Navigation Links
Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma
Date:9/15/2008

;

-- the safety and efficacy of the Company's products or product

candidates;

-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

-- the Company's ability to develop, manufacture, license and sell its

products or product candidates;

-- the Company's ability to enter into and successfully execute license

and collaborative agreements, if any;

-- the adequacy of the Company's capital resources and cash flow

projections, the Company's ability to obtain sufficient financing to

maintain the Company's planned operations, or the Company's risk of

bankruptcy if it is unsuccessful in obtaining such financing or in

securing shareholder approval to increase the number of shares

authorized for issuance under the Company's certificate of

incorporation, as required by the transactional documents in our recent

financing;

-- the adequacy of the Company's patents and proprietary rights;

-- the impact of litigation that has been brought against the Company and

any proposed settlement of such litigation; and

-- the other risks described under Certain Risks and Uncertainties Related

to the Company's Business, as contained in the Company's Annual Report

on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2007 and its most recent quarterly report on Form 10-Q.

CONTACT:

Genta Investor Relations

info@genta.com


'/>"/>
SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. InterCure and Mashco Announce Launch into Independent Pharmacies in the United Kingdom
5. Mindray Announces Appointment of Dr. Jixun Lin as Independent Director
6. Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting
7. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R)
8. Kiwa Fertilizers Pass Independent Tests
9. Amarin Appoints Dr. William Mason as Lead Independent Director
10. China Pharma Appoints Three Independent Non-Executive Directors
11. China Technology Appoints Deloitte Touche Tohmatsu CPA as Independent Auditor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2014)... (PRWEB) August 23, 2014 ... Partners LLC announced today that Janet B. Arrowsmith, ... Expert consultant. NDA Partners Premier Experts are top ... them to bring extraordinary value to the company’s ... critical solutions to help clients successfully develop their ...
(Date:8/22/2014)... This is a professional and ... Papain industry in Global and China. The report ... definitions, applications and industry chain structure. Global market ... with a focus on history, developments, trends and ... the international and Chinese situation is also offered. ...
(Date:8/22/2014)... Today the Academy of Model Aeronautics (AMA) ... of Appeals for the D.C. Circuit challenging the FAA’s Interpretation ... Federal Register on June 25, 2014. , The AMA ... text and intent of the FAA Modernization and Reform Act ... on any new rules or regulations regarding model aircraft that ...
(Date:8/22/2014)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced results for ... complete 2014 second quarter financial statements and MD&A have been filed on ... 30, , Six-months ended June 30, ( in CDN$,000 except ... , 2014 , 2013 Revenue , 2,459 ... profit , 56 , 1,485 , 385 ...
Breaking Biology Technology:Noted Epidemiologist and Former FDA Deputy Director Janet B. Arrowsmith, MD, Joins NDA Partners as a Premier Expert Consultant 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 3AMA Files Petition for Review of FAA’s Interpretive Rule 2Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3
... Inc.,(Nasdaq: NGSX ), a biopharmaceutical company focused ... today that,Anthony DiTonno, President and Chief Executive Officer, ... Healthcare Unplugged Conference in New,York City on Tuesday, ... Financial Officer, will be available to respond to ...
... BETHESDA, Md., Sept. 2 Micromet, Inc.,(Nasdaq: ... company,developing novel, proprietary antibodies for the treatment of ... of,Barclay A. Phillips as Senior Vice President and ... member of the Company,s board of directors,since 2000, ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) ... Administration (FDA) review, the Company is initiating ... administration of REOLYSIN(R) in,combination with paclitaxel and ... (NSCLC) with K-RAS or EGFR-activated tumours. The ...
Cached Biology Technology:NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference 2NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference 3Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 2Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 3Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 4Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 2Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 3Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 4
(Date:8/22/2014)... 2014 Research ... the addition of the  "Biometrics Market ... their offering.       (Logo: ... technology that helps in the identification ... or behavioral features. It involves verification ...
(Date:8/22/2014)... Thomson Reuters , a leading source of information ... the University of California, Riverside in its 2014 list ... our times." , To generate the list, the company ... researchers whose published work has had enormous impact. , ... 3,200 individuals who published the greatest number of highly ...
(Date:8/22/2014)... La Jolla, CA Research presented at the ... therapy being developed by Hera Therapeutics Inc. combats ... that cause 70 percent of all cervical cancer. ... models, HTI-1968 blocked the replication of HPV-16, HPV-18 ... Ph.D. and Thomas Broker, Ph.D., who presented the ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... been identified in sediment-laden marine environments, conditions previously believed to ... that Middle Reef part of Australia,s iconic Great Barrier ... in areas with lower levels of sediment stress. Led ... team of scientists is published today (1 August 2012) in ...
... from the Wildlife Conservation Society (WCS) and the National Research ... called an imperial cormorant with a small camera, then watched ... in 40 seconds, feeding on the ocean floor for 80 ... to the surface 40 seconds later. This is the ...
... appendages that plague many people in the winter and an ... for singles and couples alike. In a new study, scientists ... Nationwide Children,s Hospital have identified a biological mechanism that may ... of molecules and receptors on smooth muscle cells that line ...
Cached Biology News:Coral reef thriving in sediment-laden waters 2Are cold feet plaguing your relationship? 2Are cold feet plaguing your relationship? 3
... imaging system from Molecular Devices is ... for automated acquisition and analysis of ... ImageXpressULTRA is powered by MetaXpress, ... acquisition, image storage and analysis. MetaXpress ...
... Bioimager is an automated, confocal, real-time, single ... has been integrated into a single, compact ... to provide high-resolution, automated confocal imaging with ... better cell-based assays. The system allows the ...
... uses a simplified procedure and streamlines the ... kit is based on the three step ... sodium bisulfite where cytosine is converted into ... in-column desulphonation reaction eliminates several precipitation steps ...
... The DIGIVIEW line of digital x-ray detectors ... imaging device complete with 12 to 16 ... consists of a photodiode array sensor with ... models are available in low x-ray energies ...
Biology Products: